Mechanisms of Abrupt Loss of Virus Control in a Cohort of Previous HIV Controllers
暂无分享,去创建一个
R. Paredes | À. Olvera | C. Brander | Muntsa Rocafort | M. Fernández | M. Crespo | J. Alcamí | J. del Romero | A. Llano | B. Mothe | L. Dorrell | M. Ruiz-Riol | R. Bellido | P. Cobarsí | Míriam Rosás-Umbert | Patricia Cobarsí
[1] M. Lederman,et al. HIV-1 proviral landscapes distinguish posttreatment controllers from noncontrollers , 2018, The Journal of clinical investigation.
[2] B. Walker,et al. The Control of HIV After Antiretroviral Medication Pause (CHAMP) Study: Posttreatment Controllers Identified From 14 Clinical Studies , 2018, The Journal of infectious diseases.
[3] B. Clotet,et al. Control of HIV-1 Pathogenesis in Viremic Nonprogressors Is Independent of Gag-Specific Cytotoxic T Lymphocyte Responses , 2018, Journal of Virology.
[4] M. C. Ortiz,et al. Class-modeling analysis reveals T-cell homeostasis disturbances involved in loss of immune control in elite controllers , 2018, BMC Medicine.
[5] Todd M. Allen,et al. Rapid HIV disease progression following superinfection in an HLA-B*27:05/B*57:01-positive transmission recipient , 2018, Retrovirology.
[6] J. Prado,et al. Factors Leading to the Loss of Natural Elite Control of HIV-1 Infection , 2017, Journal of Virology.
[7] M. Lederman,et al. Impaired human immunodeficiency virus type 1 replicative fitness in atypical viremic non-progressor individuals , 2017, AIDS Research and Therapy.
[8] M. Carrington,et al. Factors Associated With the Control of Viral Replication and Virologic Breakthrough in a Recently Infected HIV-1 Controller , 2017, EBioMedicine.
[9] R. Paredes,et al. Plasma HIV-1 Tropism and the Risk of Short-Term Clinical Progression to AIDS or Death , 2014, PloS one.
[10] B. Walker,et al. CD8+ T Cell Breadth and Ex Vivo Virus Inhibition Capacity Distinguish between Viremic Controllers with and without Protective HLA Class I Alleles , 2016, Journal of Virology.
[11] Felipe García,et al. Rate and predictors of progression in elite and viremic HIV-1 controllers , 2016, AIDS.
[12] Marion C Lanteri,et al. Human memory T cells with a naïve phenotype accumulate with aging and respond to persistent viruses , 2016, Nature Immunology.
[13] M. Lederman,et al. The size of the expressed HIV reservoir predicts timing of viral rebound after treatment interruption , 2015, AIDS.
[14] Kathleen V Fitch,et al. Reduced ovarian reserve relates to monocyte activation and subclinical coronary atherosclerotic plaque in women with HIV , 2015, AIDS.
[15] A. Westfall,et al. Normal T-cell activation in elite controllers with preserved CD4+ T-cell counts , 2015, AIDS.
[16] M. Johnson,et al. Circulating microRNAs in Sera Correlate with Soluble Biomarkers of Immune Activation but Do Not Predict Mortality in ART Treated Individuals with HIV-1 Infection: A Case Control Study , 2015, PloS one.
[17] P. Uhlén,et al. Infection by Toxoplasma gondii Induces Amoeboid-Like Migration of Dendritic Cells in a Three-Dimensional Collagen Matrix , 2015, PloS one.
[18] L. Meyer,et al. Immunologic and Virologic Progression in HIV Controllers: The Role of Viral “Blips” and Immune Activation in the ANRS CO21 CODEX Study , 2015, PloS one.
[19] M. Biffoni,et al. Two-Year Follow-Up of Macaques Developing Intermittent Control of the Human Immunodeficiency Virus Homolog Simian Immunodeficiency Virus SIVmac251 in the Chronic Phase of Infection , 2015, Journal of Virology.
[20] S. Le Gall,et al. Variable Processing and Cross-presentation of HIV by Dendritic Cells and Macrophages Shapes CTL Immunodominance and Immune Escape , 2015, PLoS pathogens.
[21] D. Follmann,et al. CD8+ T-cell Cytotoxic Capacity Associated with Human Immunodeficiency Virus-1 Control Can Be Mediated through Various Epitopes and Human Leukocyte Antigen Types , 2014, EBioMedicine.
[22] Andrew R. Jones,et al. Allele frequency net 2015 update: new features for HLA epitopes, KIR and disease and HLA adverse drug reaction associations , 2014, Nucleic Acids Res..
[23] Angela R. McLean,et al. Impact of HLA-driven HIV adaptation on virulence in populations of high HIV seroprevalence , 2014, Proceedings of the National Academy of Sciences.
[24] H. Schuitemaker,et al. Characterisation of long-term non-progression of HIV-1 infection after seroconversion: a cohort study. , 2014, The lancet. HIV.
[25] À. Olvera,et al. HLA-B*35-PX and HLA-B*35-PY subtype differentiation does not predict observed differences in level of HIV control in a Peruvian MSM cohort. , 2014, AIDS.
[26] J. Blankson,et al. Comparative Analysis of the Capacity of Elite Suppressor CD4+ and CD8+ T Cells To Inhibit HIV-1 Replication in Monocyte-Derived Macrophages , 2014, Journal of Virology.
[27] R. Paredes,et al. Switching the third drug of antiretroviral therapy to maraviroc in aviraemic subjects: a pilot, prospective, randomized clinical trial. , 2013, The Journal of antimicrobial chemotherapy.
[28] B. Angus,et al. Improved quantification of HIV-1-infected CD4+ T cells using an optimised method of intracellular HIV-1 gag p24 antigen detection. , 2013, Journal of immunological methods.
[29] R. Swanstrom,et al. HIV-1 pathogenesis: the virus. , 2012, Cold Spring Harbor perspectives in medicine.
[30] B. Burwitz,et al. CD8+ and CD4+ cytotoxic T cell escape mutations precede breakthrough SIVmac239 viremia in an elite controller , 2012, Retrovirology.
[31] B. Walker,et al. HIV and HLA class I: an evolving relationship. , 2012, Immunity.
[32] A. McMichael,et al. Antiviral inhibitory capacity of CD8+ T cells predicts the rate of CD4+ T-cell decline in HIV-1 infection. , 2012, The Journal of infectious diseases.
[33] D. Heckerman,et al. CTL Responses of High Functional Avidity and Broad Variant Cross-Reactivity Are Associated with HIV Control , 2012, PloS one.
[34] M. Nei,et al. MEGA5: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. , 2011, Molecular biology and evolution.
[35] D. Kaufmann,et al. HIV controllers: a multifactorial phenotype of spontaneous viral suppression. , 2011, Clinical immunology.
[36] J. Prado,et al. Immune correlates of HIV control. , 2011, Current medicinal chemistry.
[37] S. Elahi,et al. Protective HIV-specific CD8+ T cells evade Treg cell suppression , 2011, Nature Medicine.
[38] F. Pereyra,et al. High-Functional-Avidity Cytotoxic T Lymphocyte Responses to HLA-B-Restricted Gag-Derived Epitopes Associated with Relative HIV Control , 2011, Journal of Virology.
[39] J. Mellors,et al. HIV-1 Continues To Replicate and Evolve in Patients with Natural Control of HIV Infection , 2010, Journal of Virology.
[40] A. Telenti,et al. HIV-1 elite controllers: beware of super-infections. , 2010, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.
[41] B. Agan,et al. Clinical outcomes of elite controllers, viremic controllers, and long-term nonprogressors in the US Department of Defense HIV natural history study. , 2009, The Journal of infectious diseases.
[42] Elizabeth T. Cirulli,et al. Common Genetic Variation and the Control of HIV-1 in Humans , 2009, PLoS genetics.
[43] Christian Brander,et al. Virological, Immune and Host genetics Markers in the Control of HIV Infection , 2009, Disease markers.
[44] David W. Haas,et al. HLA-Associated Immune Escape Pathways in HIV-1 Subtype B Gag, Pol and Nef Proteins , 2009, PloS one.
[45] C. Rouzioux,et al. Heterogeneity in HIV Suppression by CD8 T Cells from HIV Controllers: Association with Gag-Specific CD8 T Cell Responses1 , 2009, The Journal of Immunology.
[46] H. Schuitemaker,et al. Recovery of viremic control after superinfection with pathogenic HIV type 1 in a long-term elite controller of HIV type 1 infection. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[47] Todd M. Allen,et al. Immune-driven recombination and loss of control after HIV superinfection , 2008, The Journal of experimental medicine.
[48] Steven G. Deeks,et al. HLA Class I-Restricted T-Cell Responses May Contribute to the Control of Human Immunodeficiency Virus Infection, but Such Responses Are Not Always Necessary for Long-Term Virus Control , 2008, Journal of Virology.
[49] Terri Wrin,et al. Genetic and immunologic heterogeneity among persons who control HIV infection in the absence of therapy. , 2008, The Journal of infectious diseases.
[50] Jeffrey N. Martin,et al. Relationship between T cell activation and CD4+ T cell count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy. , 2008, The Journal of infectious diseases.
[51] B. Walker,et al. Human immunodeficiency virus controllers: mechanisms of durable virus control in the absence of antiretroviral therapy. , 2007, Immunity.
[52] Jacques Fellay,et al. A Whole-Genome Association Study of Major Determinants for Host Control of HIV-1 , 2007, Science.
[53] H. Schuitemaker,et al. Low Immune Activation despite High Levels of Pathogenic Human Immunodeficiency Virus Type 1 Results in Long-Term Asymptomatic Disease , 2007, Journal of Virology.
[54] P. Kaleebu,et al. Relation Between Chemokine Receptor Use, Disease Stage, and HIV-1 Subtypes A and D: Results From a Rural Ugandan Cohort , 2007, Journal of acquired immune deficiency syndromes.
[55] Asier Sáez-Cirión,et al. HIV controllers exhibit potent CD8 T cell capacity to suppress HIV infection ex vivo and peculiar cytotoxic T lymphocyte activation phenotype , 2007, Proceedings of the National Academy of Sciences.
[56] Philip J. R. Goulder,et al. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression , 2006, Nature.
[57] Bette T. Korber,et al. Relative Dominance of Gag p24-Specific Cytotoxic T Lymphocytes Is Associated with Human Immunodeficiency Virus Control , 2006, Journal of Virology.
[58] S. Lewin,et al. Enhanced Replicative Capacity and Pathogenicity of HIV-1 Isolated From Individuals Infected With Drug-Resistant Virus and Declining CD4+ T-Cell Counts , 2005, Journal of acquired immune deficiency syndromes.
[59] Eric J. Arts,et al. Changes in Human Immunodeficiency Virus Type 1 Fitness and Genetic Diversity during Disease Progression , 2005, Journal of Virology.
[60] A. Trkola,et al. Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies , 2005, Nature Medicine.
[61] D. Richman,et al. Incidence of HIV superinfection following primary infection. , 2004, JAMA.
[62] Peter Hunt,et al. Immune activation set point during early HIV infection predicts subsequent CD4+ T-cell changes independent of viral load. , 2004, Blood.
[63] S. Migueles,et al. The Functional Profile of Primary Human Antiviral CD8+ T Cell Effector Activity Is Dictated by Cognate Peptide Concentration , 2004, The Journal of Immunology.
[64] F. M. Marincola,et al. Consistent Cytotoxic-T-Lymphocyte Targeting of Immunodominant Regions in Human Immunodeficiency Virus across Multiple Ethnicities , 2004, Journal of Virology.
[65] Stephen J O'Brien,et al. The influence of HLA genotype on AIDS. , 2003, Annual review of medicine.
[66] Todd M. Allen,et al. HIV-1 superinfection despite broad CD8+ T-cell responses containing replication of the primary virus , 2002, Nature.
[67] F. Marincola,et al. HLA B*5701 is highly associated with restriction of virus replication in a subgroup of HIV-infected long term nonprogressors. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[68] B. Walker,et al. The great escape – AIDS viruses and immune control , 1999, Nature Medicine.
[69] S. Buchbinder,et al. Long‐term HIV‐1 infection without immunologic progression , 1994, AIDS.
[70] M. Nei,et al. Estimation of the number of nucleotide substitutions in the control region of mitochondrial DNA in humans and chimpanzees. , 1993, Molecular biology and evolution.
[71] D. Ho,et al. Increased viral burden and cytopathicity correlate temporally with CD4+ T-lymphocyte decline and clinical progression in human immunodeficiency virus type 1-infected individuals , 1993, Journal of virology.
[72] N. Saitou,et al. The neighbor-joining method: a new method for reconstructing phylogenetic trees. , 1987, Molecular biology and evolution.
[73] J. Felsenstein. CONFIDENCE LIMITS ON PHYLOGENIES: AN APPROACH USING THE BOOTSTRAP , 1985, Evolution; international journal of organic evolution.